

Autosomal Dominant Tubulointerstitial Kidney Disease



Anthony J. Bleyer, Kendrah Kidd, Martina Živná, and Stanislav Kmoch

There are 3 major forms of autosomal dominant tubulointerstitial kidney disease (ADTKD): ADTKD due to *UMOD* mutations, *MUC1* mutations, and mutations in the *REN* gene encoding renin. Lack of knowledge about these conditions contributes to frequent nondiagnosis, but with even limited knowledge, nephrologists can easily obtain a diagnosis and improve patient care. There are 3 cardinal features of these disorders: (1) the conditions are inherited in an autosomal dominant manner and should be considered whenever both a parent and child suffer from kidney disease; the presence of even more affected family members provides further support. (2) These conditions are associated with a bland urinary sediment, ruling out glomerular disorders. (3) There is a variable rate of decline in kidney function. The mean age of ESRD is approximately 45, but the range is from 17 to >75. ADTKD-*UMOD* is often but not always associated with gout in the teenage years. ADTKD-*REN* is associated with signs of hyporeninemia: mild hypotension, mild hyperkalemia, anemia in childhood, and hyperuricemia and gout in the teenage years. The only clinical manifestation of ADTKD-*MUC1* is slowly progressive CKD. Diagnosis should be made by genetic testing, and kidney biopsy should be avoided.

© 2016 by the National Kidney Foundation, Inc. All rights reserved.

Key Words: Autosomal dominant, Tubulointerstitial, Renin, Uromodulin, Mucin-1

Autosomal dominant tubulointerstitial kidney disease (ADTKD) refers to disorders with the following characteristics: (1) autosomal dominant inheritance, (2) bland urinary sediment with no or trace proteinuria, and (3) slowly progressive CKD with a variable age of onset of ESRD, ranging from ages 17 to >75 (see Table 1). There are 3 major subgroups of ADTKD. ADTKD-*UMOD* is caused by mutations in the *UMOD* gene encoding uromodulin (Tamm-Horsfall glycoprotein) and associated with a high prevalence of adolescent gout; ADTKD-*MUC1* is caused by mutations in the *MUC1* gene encoding mucin-1. ADTKD-*REN* is caused by mutations in the *REN* gene that encodes renin and is associated with signs of relative hyporeninemia.

CASE EXAMPLE

A 21-year-old white man is referred for evaluation of an elevated serum creatinine level of 1.4 mg/dL (124 mmol/L), which was found as part of routine laboratory studies for a life insurance physical. The patient is otherwise healthy, on no medications, and has no known risk factors for kidney disease. The patient's father required kidney transplantation at age 45, and the patient's paternal uncle has CKD at the age of 55. The paternal grandfather died at 70 of kidney failure before the advent of dialysis. Physical examination is unremarkable, and the patient's urinalysis surprisingly reveals no protein or blood. A kidney ultrasound is normal. A kidney biopsy is performed and

is nondiagnostic, revealing tubulointerstitial scarring without an inflammatory infiltrate. A diagnosis of hereditary nephrosclerosis is made. Several months later, the patient attends a family reunion and finds out that several of his family members have been diagnosed with ADTKD-*MUC1*. He undergoes *MUC1* genetic testing and is found to have a mutation in the *MUC1* gene.

GENERAL PRINCIPLES IN DIAGNOSIS

The key diagnostic feature of ADTKD is the presence of at least an affected parent and child with CKD. From a clinical standpoint, the lifetime chance for a white individual of developing ESRD is about 3.6%.¹ The chance that 2 individuals from the same family will have different kidney diseases and develop ESRD is about 1 in 1000, whereas the chance that the child of an affected individual will have kidney disease due to an autosomal dominant inherited disorder is 1 in 2. Thus, when a parent and child have kidney disease, autosomal dominant disorders should be strongly considered. Once the inheritance pattern has been identified, it is important to evaluate the urine. The presence of blood or protein in the urine suggests a hereditary glomerular disorder, such as Alport syndrome. The presence of a bland urinary sediment suggests ADTKD. In the vast majority of patients with ADTKD, there is no proteinuria or trace proteinuria. Occasional individuals may have proteinuria up to 500 mg/d. A kidney biopsy is usually nonspecific in ADTKD, showing interstitial scarring with the absence of glomerular disease or an inflammatory infiltrate. These findings are not pathognomonic for ADTKD, and thus, a definitive diagnosis cannot be made. For this reason, genetic analysis is the preferred diagnostic approach.

Why is it important to pursue a genetic diagnosis? (1) Once a genetic diagnosis is established, family members who wish to donate a kidney can be tested for the genetic mutation to see if they qualify as donors. In both ADTKD-*MUC1* and ADTKD-*UMOD*, affected individuals may have normal serum creatinine values past age 20, and there

From the Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC; Institute for Inherited Metabolic Disorders, Prague, Czech Republic; and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

Financial Disclosure: See Acknowledgment(s) on page 92.

Address correspondence to Anthony J. Bleyer, MD, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157. E-mail: ableyer@wakehealth.edu

© 2016 by the National Kidney Foundation, Inc. All rights reserved.

1548-5595/\$36.00

<http://dx.doi.org/10.1053/j.ackd.2016.11.012>

are at least 3 cases known to the authors of affected individuals being kidney donors to family members. (2) Identifying a genetic diagnosis is helpful in establishing follow-up and preventing kidney biopsies for diagnosis in other family members. (3) For ADTKD-REN, specific therapies are available, and for ADTKD-UMOD, family members may wish to consider taking allopurinol (see "ADTKD-UMOD: Treatment"). (4) Once a disease is diagnosed, family members may wish to work with groups that are trying to identify treatments for these disorders. (5) ADTKD has affected many families for generations. Often, affected individuals simply want to know the specific cause of their disorder.

Rare inherited disorders may be difficult for the nephrologist to diagnose as there are a large number of these conditions, and new ones continue to be identified. Both patients and nephrologists may initiate data searches on the Internet to identify the causes of such conditions. For some rare disorders, patient-led foundations or clinical centers may have a specific interest and may have developed excellent, informative Web sites. Unfortunately, many Web sites regarding these conditions may be outdated or inaccurate. Web sites from many medical centers often provide limited, generic text that serves as a form of advertisement and are unhelpful. It is, therefore, important that patients and physicians have access to current information about these disorders. Resources that are highly reliable and provide pertinent accurate information when performing such a search include UpToDate, GeneReviews, and PubMed. Searching these sites will usually provide a clue to the diagnosis. If these sites are unhelpful, a search of the

Internet may still be used. For ADTKD, we recommend the following Web sites: <http://www.uptodate.com/contents/autosomal-dominant-tubulointerstitial-kidney-disease-medullary-cystic-kidney-disease>, <http://kdigo.org/home/conferences/adtkd/>, <http://rarediseases.org/rare-diseases/autosomal-dominant-interstitial-kidney-disease/>, http://www.ukdcure.org/learn_more, <https://ghr.nlm.nih.gov/condition/uromodulin-associated-kidney-disease>, and <http://www.wakehealth.edu/Nephrology/Medullary-Kidney-Disease/Research-Team-Mucin-1-Kidney-Disease.htm>.

The conditions causing ADTKD are rare, but because of the autosomal dominant inheritance, a significant number of family members may be affected. Thus, obtaining a diagnosis in 1 family member will be beneficial to many other family members who may be affected. Once a diagnosis is made, it is important to contact other potentially affected family members and provide information regarding the specific familial condition. Often, unaffected family members believe the condition can "skip a generation" and live

under a persistent fear that their children will develop kidney failure. Thus, providing information to all family members, including unaffected individuals, is important. Although it is important to inform other family members of the possibility they may have the condition, the decision for genetic testing is personal. At present, there are no specific treatments for ADTKD other than ADTKD-REN. Testing of children for genetic conditions in which a specific therapy is unavailable is discouraged.²

ADTKD-UMOD

ADTKD-UMOD is considered a rare disease, with less than 2000 families identified worldwide with this disorder.

Clinical Manifestations

The most common manifestations of ADTKD-UMOD include hypouricosuric hyperuricemia and CKD. It is important to note that hyperuricemia is present in most but not all individuals and families with this condition.³ Affected individuals frequently have an elevated serum urate level early in life, resulting from decreased urinary uric acid excretion.⁴ In the early-to-late teen years, patients may develop gout. The symptoms are typical of those found in older individuals, with the big toe or ankle often being affected. Gout is often misdiagnosed by clinicians as overexertion or a sports injury. As there is frequently a strong family history of gout, family members often make the diagnosis. As patients grow older, glomerular filtration rate declines. There is a large variation in the rate of progression of kidney disease that remains unexplained. The mean age

for starting dialysis in our cohort is 47 years, with a range of 19 to >75.

Genetics and Pathophysiology

Mutations in the *UMOD* gene encoding uromodulin (also known as Tamm-Horsfall glycoprotein) have been identified as the cause of ADTKD-UMOD.⁵ Uromodulin is a membrane-anchored protein that is expressed only in tubular cells in the thick ascending limb of Henle.⁶ The uromodulin protein has a very high cysteine content. As it traverses the endoplasmic reticulum, the cysteine residues form disulfide bonds that allow the protein to achieve its final conformation.⁷ The protein is then transported to the apical surface of the tubular cell where it is anchored to the membrane initially. Uromodulin then undergoes extracellular enzymatic cleavage and is excreted in the urine.⁸

Although uromodulin has been studied for over 5 decades,⁹ its function remains unclear. A genome-wide association study suggested that uromodulin may have a very mild effect on the risk of kidney stone development.¹⁰

CLINICAL SUMMARY

- There are 3 primary causes of autosomal dominant tubulointerstitial kidney disease (ADTKD): mutations in the *UMOD* gene encoding uromodulin (Tamm-Horsfall glycoprotein), mutations in the *REN* gene encoding renin, and mutations in the *MUC1* gene encoding mucin-1.
- These conditions should be suspected if both a parent and child have kidney disease and if the urinalysis reveals a bland sediment.
- In all 3 conditions, there is a variable rate of progression of CKD, with the age of onset of end-stage kidney disease ranging from 17 to ≥ 75 years.

Table 1. Characteristics of 3 Major Causes of Autosomal Dominant Tubulointerstitial Kidney Disease

Characteristic	ADTKD- <i>UMOD</i>	ADTKD- <i>MUC1</i>	ADTKD- <i>REN</i>
Abbreviated name	Uromodulin Kidney Disease (ADTKD- <i>UMOD</i>)	Mucin-1 Kidney Disease (ADTKD- <i>MUC1</i>)	ADTKD- <i>REN</i>
Inheritance	Autosomal dominant	Autosomal dominant	Autosomal dominant
Urinary sediment	Bland	Bland	Bland
Gout	May occur in childhood; frequent	Occurs in advanced CKD, similar to other kidney diseases	May occur in childhood; frequent
Other symptoms	None	None	Anemia, mild hyperkalemia, mild hypotension, prone to acute kidney injury
Age of ESRD	47 (19 to >75)	43 (17 to >75)	50 (30 to >60)
Knockout mouse	No disease	No disease	Lethal mutation
Pathophysiology	Intracellular deposition of mutated uromodulin leading to CKD	Intracellular deposition of mutated mucin-1 leading to CKD	Intracellular deposition of mutated renin
Diagnosis	Genetic testing at commercial laboratory	Contact ableyer@wakehealth.edu	Genetic testing at research laboratory
Treatment	Allopurinol to prevent gout; may slow progression of CKD	No known treatment	High sodium diet or fludrocortisone

Studies of uromodulin knockout mice have shown that they are prone to urinary tract infection when their bladders are instilled with bacteria.¹¹ However, it is important to point out that in individuals who have *UMOD* mutations—and produce very little uromodulin—an increased risk of urinary tract infections or nephrolithiasis has not been reported.⁴ Recent investigations have uncovered a more important role for uromodulin. Laboratory studies have shown that uromodulin facilitates the transport of the furosemide-sensitive NKCC2 transporter to the surface of the thick ascending limb.¹² In addition, Mutig and colleagues¹² demonstrated that uromodulin enhances the phosphorylation of NKCC2, which increases NKCC2 activity and sodium absorption. Approximately 15% of the general population has a minor genetic variant in the *UMOD* promoter that results in decreased uromodulin production compared with the major variant found in 85% of the population. Because of increased sodium excretion, these individuals with the minor variant have lower blood pressure readings, better kidney function, and less tubulointerstitial fibrosis later in life than the 85% of individuals who have the major variant and produce more uromodulin.¹³ These findings point to the importance of uromodulin in modulating sodium reabsorption in the thick ascending limb. Decreased uromodulin function or production results in decreased NKCC2 translocation to the apical surface, decreased sodium reabsorption, and increased sodium excretion.

Affected individuals with ADTKD-*UMOD* have 1 normal *UMOD* allele and 1 mutant allele. They suffer from both decreased production of normal uromodulin and the production of abnormal uromodulin. Decreased production of normal uromodulin results in decreased transport of the furosemide-sensitive transporter to the apical surface of the thick ascending limb of Henle. Patients develop a mild natriuresis that is compensated for by increased proximal tubular sodium uptake. This proximal tubular sodium uptake is coupled with increased

proximal tubular urate uptake. In this manner, volume homeostasis is maintained, but patients develop hypouricemic hyperuricemia, which leads to gout early in life.⁵

In addition to a decrease in normal uromodulin production, patients also suffer from intracellular deposition of mutant uromodulin, which is central to the pathogenesis of kidney disease. Mutations in the *UMOD* gene result in the addition or a deletion of a cysteine residue in approximately half of all mutations that have been identified.¹⁴ In all cases, the mutations result in amino acid changes that prevent the uromodulin molecule from folding correctly. The mutant uromodulin deposits within the cell, leading to accelerated apoptosis and cell death.¹⁵ Tubular cell death is followed by nephron dropout, kidney fibrosis, and progressive CKD leading to ESRD. Mutations that result in truncation or lack of synthesis of uromodulin do not cause ADTKD-*UMOD*,¹⁴ and uromodulin knockout mice have no or mild kidney disease,¹⁶ showing that the deposition of the mutant uromodulin appears central to the pathogenesis and loss of kidney function.

Diagnosis

Uromodulin kidney disease should be suspected in individuals with a family history of kidney disease and a bland urinary sediment. Sometimes, the diagnosis can be made based on the appropriate clinical picture and knowledge that another family member has undergone genetic testing and has been identified with a *UMOD* mutation.¹⁷ Otherwise, uromodulin genetic analysis is available at commercial clinical laboratories.¹⁸ When ordering *UMOD* genetic analysis, providing the laboratory with the family mutation, if known, will lower the cost of genetic analysis.

Treatment

Gout and hyperuricemia in patients with ADTKD-*UMOD* is easily treated with allopurinol or febuxostat.¹⁷ Any affected individuals who develop gout should be started on one of these agents to prevent future gout

attacks and the development of gouty tophi. Early reports suggested that allopurinol might slow progression of CKD.¹⁹ It has subsequently become apparent that allopurinol will not stop progression, and it remains unclear if it will slow progression. It is important that physicians discuss the risk/benefit ratio with the parents of affected children. Starting allopurinol early in life will prevent gout from developing later and life and may be helpful in slowing progression of kidney disease. These benefits must be balanced against the rare risk of severe allergic reaction to allopurinol. In addition, it is extremely important to warn all women of child-bearing age that allopurinol may possibly have some teratogenic effects and should be stopped before pregnancy.²⁰

As kidney disease progression is slow and *UMOD* mutations affect only the kidneys, patients are excellent candidates for kidney transplantation. "Family members wishing to donate should undergo *UMOD* mutational analysis before donation, even if they appear to have normal kidney function." Every effort should be made to have patients with *ADTKD-UMOD* undergo preemptive transplantation. It is important to note that the disease will not recur in the transplanted kidney.

Future Directions

We are studying genetic variants in the promoter of the *UMOD* gene to determine if they are responsible for the wide variation in age of ESRD seen in individuals with *ADTKD-UMOD*. We are hoping to conduct a genome-wide association study to determine other genetic factors that may affect the age of onset of kidney failure. This study will require DNA samples on approximately 1000 individuals with *ADTKD-UMOD*. Please consider referring any families with known or suspected *ADTKD-UMOD* to us for participation in this study.

ADTKD-MUC1

ADTKD-MUC1 is considered a rare disease, with less than 1000 families identified worldwide with this disorder.²¹

Clinical Manifestations

Affected individuals have slowly progressive CKD as the sole manifestation. The deterioration of kidney function is highly variable both within and between families.²² The mean age of onset of ESRD in our cohort is 43 years, ranging from 17 to >75. The variation can be quite significant even between an affected parent and child. We have seen some cases where the child is on dialysis in their 30s and the 60-year-old affected parent only has Stage III CKD. An elevated serum creatinine usually is first identified in the late teens or early 20s. Over time, the serum creatinine slowly increases. Patients have no other symptoms from this disease, and the urinary sediment is bland. The kidney ultrasound is unremarkable. Hypertension, gout, anemia, and progressive deterioration of kidney size occur in a similar manner and with a similar frequency as found in patients with other forms of CKD.²³ In some patients, there is an acceleration in the loss of eGFR when it decreases less than 30 mL/min/1.73 m².

Genetics

Identification of the genetic cause of *ADTKD-MUC1* was exceedingly difficult, and only recently was a mutation in the *MUC1* gene encoding mucin-1 identified as the genetic cause of this condition.²¹ Mucin-1 is a mucoprotein with 2 components.²⁴ There is an intracellular and membrane-spanning domain with an extracellular component. The extracellular component is formed by a 20-125 repetitive sequence units of 20 amino acids. This segment is rich in serine, proline, and threonine residues, which allow for extensive glycosylation, giving mucin its adherent and protective properties. The other component of mucin-1 is an intracellular portion that associates with the membrane spanning domain and is responsible for cell signaling. Mucin-1 is found on the apical surface of many epithelial cells throughout the body, including in the gastrointestinal tract, mammary glands, respiratory tract, and sebaceous glands of the skin. Mucin-1 is also expressed in the thick ascending limb and distal convoluted tubule.

Most families with *ADTKD-MUC1* have a cytosine insertion within a tract of 7 cytosines within a repetitive 60 nucleic acid sequence that codes for the 20 amino acid repetitive amino acid sequence described earlier.²¹ The cytosine insertion results in the creation of a specific, self-terminating frameshift peptide. This peptide carries a very high positive charge and deposits intracellularly. All patients with this disorder create the same specific frameshift peptide. No affected families have been found to have a missense or nonsense mutation that results in truncation of the protein or the creation of a different frameshift peptide. Thus, this specific frameshift peptide is central to the pathogenesis of *ADTKD-MUC1*. In affected individuals, this mutated protein is deposited in cells throughout the body, but for some reason, clinical consequences are limited to the kidney. Here, the frameshift peptide deposits within the cells and leads to accelerated apoptosis, tubular cell death, nephron dropout, and progressive CKD.

At present, only the cytosine insertion in the 7 cytosine tract can be determined by genetic analysis. We believe that other mutations that produce the same frameshift peptide (eg, a thymidine insertion instead of a cytosine insertion) may cause *ADTKD-MUC1* and are currently undiagnosed. In a group of 21 families with clinical characteristics of *ADTKD-MUC1*, we were able to identify the *MUC1* cytosine insertion in 13.²¹ One family linked to the region of the *MUC1* gene did not have the cytosine insertion. Thus, we believe that there are families without the cytosine insertion who have *ADTKD-MUC1*, likely generating the abnormal frameshift peptide via another mutation.

Diagnosis

Clinically approved (CLIA) genetic testing for *ADTKD-MUC1* is restricted to the diagnosis of the cytosine insertion. This test is available free of charge from the Broad Institute and can be obtained by contacting A.J.B. (ableyer@wakehealth.edu). It is important to note that testing for the *MUC1* mutation is not a straightforward mutational analysis, and this test cannot be performed at

commercial clinical laboratories at this time. Investigators are working on other genetic methods to identify mutations in the *MUC1* gene.

Treatment

There is at present no specific therapy for ADTKD-*MUC1*. Optimal therapy of CKD—control of blood pressure and secondary changes of CKD—are the only available treatments. As these patients will progress to ESRD at a slow rate, and as this condition affects no other organs, these patients are excellent candidates for kidney transplantation. It is extremely important that any potential donors within the family be tested for the *MUC1* mutation, even if they appear to have normal kidney function.

Future Directions

There are many key aspects of pathophysiology that need to be understood. It is known that the *MUC1* frameshift peptide is very highly positively charged and deposits within the cytoplasm of affected cells. However, we still need to determine the relative importance of the deposition of the abnormal protein vs the loss of functioning normal mucin-1. How the *MUC1* frameshift peptide leads to pathologic changes also needs to be identified. We are also interested in determining why deposition of the *MUC1* frameshift peptide is only problematic in the kidney, even though this protein deposits in many cell types and tissues throughout the body.

From a clinical standpoint, it is unclear why there is such a wide variation in the age of onset of ESRD. This variation is seen between families, but also within families. We are trying to determine genetic and environmental factors that are responsible for these findings and are planning to perform a genome-wide association study to identify genetic factors associated with the age of onset of kidney failure.

ADTKD-*REN*

ADTKD-*REN* is a rare cause of ADTKD, with less than 20 families reported worldwide.

Clinical Manifestations

Affected individuals have 1 normal allele producing renin and another allele produces an abnormal renin precursor (preprorenin). Patients suffer from aberrant translocation of the abnormal renin precursor into the endoplasmic reticulum, which gradually reduces the viability of renin-expressing cells in kidney. In addition, the decreased production of renin because of the presence of only 1 normal renin allele results in signs of a relative decrease in renin production.

Renin augments the production of hemoglobin in childhood, and affected individuals suffer from anemia from the first year of life.²⁵ Hemoglobin levels range from 8 to 11 g/dL. Often, the cause of hypoproliferative anemia in these patients is unexplained. Serum erythropoietin levels are decreased. Some patients are clinically asymptomatic, whereas other patients receive erythropoietin, which increases hemoglobin levels. The anemia resolves as the child enters adolescence, likely because of the effects of steroid hormones on erythropoietin production. Other symptoms

of hyporeninemia also may present in childhood but are subtle. Blood pressure levels are usually on the low side, and serum potassium levels are mildly elevated. Individuals also suffer from hypouricemic hyperuricemia and may develop gout in their teenage years and are also prone to acute kidney failure in childhood. In a similar manner to patients receiving angiotensin-converting enzyme inhibitors, volume depletion and decreased renin levels can lead to acute kidney injury in individuals with ADTKD-*REN*. Acute kidney injury sometimes occurs in childhood, when volume depletion results from febrile illnesses. Patients usually recover from the acute kidney injury event, but there is some baseline CKD that is identified.

Genetics and Pathophysiology

The *REN* gene produces the renin precursor preprorenin. Preprorenin contains a signal sequence that directs endoplasmic reticulum targeting, glycosylation, and cleavage of the preprotein to form renin. In ADTKD-*REN*, affected individuals have a mutation in the signal peptide or prosegment of preprorenin. This mutation affects the targeting to or processing of preprorenin in the endoplasmic reticulum and results in reduced prorenin and renin biosynthesis and secretion. These changes lead to stress in the endoplasmic reticulum, leading to accelerated apoptosis, cell death, nephron dropout, interstitial fibrosis, and progressive loss of kidney function.

Diagnosis

Diagnosis relies on genetic testing. Renin and aldosterone levels are in the low normal range in most patients when stimulated, making this measurement inadequate for diagnosis. Genetic analysis of the *REN* gene should be used to make a diagnosis.

Treatment

Unlike other forms of ADTKD, there are several specific treatments available. First, as these patients are in a low renin state with mild hypovolemia, it is important to avoid the low sodium diet that is commonly prescribed in CKD. These patients will develop worsening hypotension and are prone to acute kidney injury on a low sodium diet. To treat the hyperkalemia and mild hypotension, a higher sodium content diet or fludrocortisone²⁶ may be beneficial. Fludrocortisone corrects the hypotension, hyperkalemia, and the hyperuricemia but does not improve the hemoglobin levels. Importantly, the fludrocortisone may lower production of renin (and the mutated renin). Decreased production of the mutated renin may slow progression of CKD.

Future Directions

We are currently studying whether fludrocortisone slows progression of CKD in individuals with ADTKD-*REN*.

ADTKD DUE TO HEPATOCYTE NUCLEAR FACTOR-1 BETA MUTATIONS

Hepatocyte nuclear factor-1 beta (HNF-1 beta) is produced by the *TCF2* gene. Mutations in this gene were first

identified as a cause of maturity-onset diabetes of youth (MODY)²⁷ with kidney manifestations later identified.

Clinical Manifestations

Identifying individuals with HNF-1 beta mutations may be difficult because of the many, varied manifestations and the fact that these manifestations are not consistently present in all affected family members, making identification of inheritance patterns and diagnosis difficult. For example, a grandfather may have had CKD leading to dialysis; his daughter may have mildly abnormal liver functions of unknown cause and a solitary kidney, and the grandchild may have bilateral cystic kidneys detected on fetal ultrasound. Thus, it is important to be familiar with the different clinical manifestations, realizing that only 1 or 2 may be present in an affected individual.

Nonrenal manifestations of ADTKD due to HNF-1 beta mutations may include: (1) MODY—although HNF-1 alpha mutations are the most common cause, HNF-1 beta mutations may also result in MODY. Patients typically present at an age <25 years and are initially noninsulin dependent. Pancreatic atrophy often develops, and patients become insulin dependent later in life. (2) Abnormal liver function studies of unclear etiology. Patients often suffer from mild elevations in alanine aminotransferase and gamma-glutamyl transpeptidase. Liver biopsy frequently reveals normal tissue and does not aid in the diagnosis. Patients retain normal hepatic function.²⁸ (3) Genitourinary tract malformations may occur. (4) Hyperuricemia and gout may occur in adolescence. (5) Hypomagnesemia occurs in some individuals. Other conditions that may be associated with this form of ADTKD include autism, chromophobe renal cell carcinoma, and early-onset hyperparathyroidism.

Kidney manifestations may begin in utero. In a study of 62 cases of fetal bilateral echogenic kidneys,²⁹ 18% of patients suffered from a *TCF2* mutation, with 15 of 18 having a complete heterozygous deletion. In adulthood, kidney manifestations are common and often involve congenital anomalies of the kidney and urinary tract.³⁰ Patients may have numerous kidney cysts, congenital solitary kidney, kidney dysplasia, or hypoplastic kidneys. Most patients have some degree of CKD. About 20% of patients will progress to ESRD. Urinalysis usually reveals less than 1 g of proteinuria/24 hours and no hematuria. The kidney manifestations are quite variable within families, which may make diagnosis difficult. Patients with this disorder can be diagnosed with genetic testing.

Pathophysiology

HNF-1 beta is encoded by the *TCF2* gene. Both the kidney and the pancreas express the homeodomain-containing transcription factors, hepatocyte nuclear factor 1 alpha and 1 beta. These genes regulate transcription of RNA and are expressed both in the pancreas and the kidneys. Massa and others³¹ inactivated HNF-1beta in the murine metanephric mesenchyme and showed that this led to marked distortion of the tubule, characterized by absence of the proximal distal tubule and loop of Henle. Thus, it is

likely that mutations in HNF-1beta affect tubular development.

Diagnosis

The key to diagnosis is the recognition of the variable presentation of each affected individual, even within families. Any of the above signs or symptoms may be present and vary within families. Mutational analysis of the *TCF2* gene is the best method of diagnosis. Faguer and colleagues have developed a 17-item score to help determine if mutational analysis should be performed.³² This score includes items such as family history, kidney morphology, and presence of the conditions discussed earlier.

Treatment

There are no specific therapies available for the underlying mutation. Treatment is supportive for CKD. For individuals with early-onset gout, one should consider agents such as allopurinol or febuxostat to prevent urate accumulation and tophus development. Screening for hyperglycemia, hypomagnesemia, hyperuricemia, and abnormal liver function tests should be carried out. A kidney ultrasound should be performed to evaluate for morphologic abnormalities. Any related individual interested in kidney transplant donation should undergo mutational analysis.

OTHER CAUSES OF ADTKD

There are a number of other autosomal dominant genetic syndromes with a spectrum of genetic abnormalities that include kidney failure and kidney structural anomalies as one of their components.

Mutations in SEC61A1

Mutations in *SEC61A1* are another cause of ADTKD.³³ Two families have been identified with this condition. In one family, intrauterine growth retardation, dysplastic kidneys, and anemia were present. In another family, CKD, anemia, and neutropenia with abscess formation were documented.

Alagille Syndrome

Alagille syndrome is due to mutations in *JAG1* or *NOTCH2*.³⁴ The condition has a variable presentation. Features include cholestasis due to decreased bile ducts, cardiac abnormalities, ocular disease, and a characteristic facial finding including prominent forehead, deep-set eyes and moderate hypertelorism, a pointed chin, and a straight nose. Cardiac abnormalities include pulmonic stenosis in two-thirds of patients and Tetralogy of Fallot, atrial septal defect, aortic stenosis, and coarctation of the aorta. Skeletal manifestations include butterfly-shaped thoracic vertebrae. Ocular abnormalities include a posterior embryotoxon (a defect in the anterior chamber of the eye) that is found in at least 75% of affected individuals. Kidney manifestations include slowly progressive CKD that can lead to dialysis. Some patients have kidney tubular acidosis. Patients should be evaluated for kidney artery stenosis, which has an increased prevalence in Alagille syndrome.

Townes-Brocks Syndrome

Townes-Brocks syndrome is due to *SALL1* mutations and is characterized by an imperforate anus, dysplastic ears, and thumb malformations. CKD also occurs in about half of the affected individuals, sometimes associated with anatomic malformations, such as reflux, cystic kidneys, or renal hypoplasia.³⁵

HDR Syndrome

HDR syndrome (hypoparathyroidism, deafness, and renal anomalies), also known as Barakat syndrome, is caused by haploinsufficiency of the *GATA3* gene. Similar to HNF-1 beta and Townes-Brocks syndrome, renal involvement is varied. Cystic kidneys, renal hypoplasia, proximal and distal kidney tubular acidosis, and nephrocalcinosis may occur.³⁶ Approximately 10% of patients will develop ESRD, at ages ranging from the second decade to the seventh decade of life.³⁷

OVERALL APPROACH TO GENETIC TESTING

UMOD mutations are the most common cause of ADTKD, and *UMOD* mutational analysis should be considered as the first genetic test if there is a family history of early gout in some members. If there is no family history of gout before CKD, mutational analysis for *MUC1* should be considered. This test is currently unavailable in clinical laboratories; please contact us for testing. Directed genetic mutational analysis for other conditions requires on the presence of associated clinical conditions. For questions on the approach to genetic testing, please contact ableyer@wakehealth.edu.

ADTKD WITH NEGATIVE GENETIC TESTING

We are aware of approximately 15 ADTKD families in whom the genetic diagnosis has not been established. If available, we initially examine kidney biopsy samples for immunohistochemical abnormalities of uromodulin, mucin-1, hepatocyte nuclear factor-1 beta, and SEC61A1 deposition. This analysis may point to mutations in already established genes that were missed by standard genetic analyses. If no genetic cause is identified, we then proceed with whole-exome/genome sequencing that may provide the diagnosis.³⁸

SUMMARY

The most important consideration in the approach to ADTKD is to achieve a definitive diagnosis by genetic testing for affected families. ADTKD should be considered when CKD affects both a parent and child, together with the absence of proteinuria or hematuria. Genetic studies are the best method to make the diagnosis.

At this time, we are recruiting as many patients with ADTKD as possible for observational and interventional studies. As these conditions are rare, we would appreciate if you would contact us regarding any families with a definitive diagnosis or potential diagnosis of ADTKD. We can help arrange genetic testing and provide free, clinical genetic testing for *MUC1* mutations.

ACKNOWLEDGMENTS

This work was supported by NIH-NIDDK R21 DK106584: Genetic Variation in Age of Onset of Kidney Failure in Uromodulin Kidney Disease. S.K. and M.Ž. were supported by the Charles University institutional programs PRVOUK-P24/LF1/3 and UNCE 204011 and by the project LQ1604 NPU II from the Ministry of Education, Youth and Sports of the Czech Republic. The remaining authors have no relevant financial disclosures.

REFERENCES

1. Grams ME, Chow EK, Segev DL, Coresh J. Lifetime incidence of CKD stages 3-5 in the United States. *Am J Kidney Dis.* 2013;62(2):245-252.
2. Ross LF, Saal HM, David KL, Anderson RR. Technical report: ethical and policy issues in genetic testing and screening of children. *Genet Med.* 2013;15(4):234-245.
3. Smith GD, Robinson C, Stewart AP, et al. Characterization of a recurrent in-frame *UMOD* indel mutation causing late-onset autosomal dominant end-stage renal failure. *Clin J Am Soc Nephrol.* 2011;6(12):2766-2774.
4. Bleyer AJ, Woodard AS, Shihabi Z, et al. Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. *Kidney Int.* 2003;64(1):36-42.
5. Hart TC, Gorry MC, Hart PS, et al. Mutations of the *UMOD* gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. *J Med Genet.* 2002;39(12):882-892.
6. Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. *Kidney Int.* 2011;80(4):338-347.
7. Serafini-Cessi F, Malagolini N, Hoops TC, Rindler MJ. Biosynthesis and oligosaccharide processing of human Tamm-Horsfall glycoprotein permanently expressed in HeLa cells. *Biochem Biophys Res Commun.* 1993;194(2):784-790.
8. Brunati M, Perucca S, Han L, et al. The serine protease hepsin mediates urinary secretion and polymerisation of zona pellucida domain protein uromodulin. *Elife.* 2015;4:e08887.
9. Tamm I, Horsfall F. Characterization and separation of an inhibitor of viral hemagglutination present in urine. *Proc Soc Exp Biol Med.* 1950;74(1):108-114.
10. Gudbjartsson DE, Holm H, Indridason OS, et al. Association of variants at *UMOD* with chronic kidney disease and kidney stones-role of age and comorbid diseases. *PLoS Genet.* 2010;6(7):e1001039.
11. Bates JM, Raffi HM, Prasad K, et al. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. *Kidney Int.* 2004;65(3):791-797.
12. Mutig K, Kahl T, Saritas T, et al. Activation of the bumetanide-sensitive Na⁺,K⁺,2Cl⁻-cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner. *J Biol Chem.* 2011;286(34):30200-30210.
13. Trudu M, Janas S, Lanzani C, et al. Common noncoding *UMOD* gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nat Med.* 2013;19(12):1655-1660.
14. Moskowitz JL, Piret SE, Lhotta K, et al. Association between genotype and phenotype in uromodulin-associated kidney disease. *Clin J Am Soc Nephrol.* 2013;8(8):1349-1357.
15. Vylet'al P, Kublova M, Kalbacova M, et al. Alterations of uromodulin biology: a common denominator of the genetically heterogeneous FJHN/MCKD syndrome. *Kidney Int.* 2006;70(6):1155-1169.
16. Raffi H, Bates JM, Laszik Z, Kumar S. Tamm-Horsfall protein knockout mice do not develop medullary cystic kidney disease. *Kidney Int.* 2006;69(10):1914-1915.

17. Eckardt KU, Alper SL, Antignac C, et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—a KDIGO consensus report. *Kidney Int.* 2015;88(4):676-683.
18. Bleyer AJ, Hart PS, Kmoch S. Autosomal dominant tubulointerstitial kidney disease, UMOD-related. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, eds. *GeneReviews*. Seattle, WA: University of Washington; 2007.
19. McBride MB, Simmonds HA, Ogg CS, et al. Efficacy of Allopurinol in ameliorating the progressive renal disease in familial juvenile hyperuricaemic nephropathy (FJHN): a six-year update. *Adv Exp Med Biol.* 1998;431:7-11.
20. Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol use during pregnancy—outcome of 31 prospectively ascertained cases and a phenotype possibly indicative for teratogenicity. *PLoS One.* 2013;8(6):e66637.
21. Kirby A, Gnirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. *Nat Genet.* 2013;45(3):288-393.
22. Bleyer AJ, Kmoch S, Antignac C, et al. Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. *Clin J Am Soc Nephrol.* 2014;9(3):527-535.
23. Stavrou C, Koptides M, Tombazos C, et al. Autosomal-dominant medullary cystic kidney disease type 1: clinical and molecular findings in six large Cypriot families. *Kidney Int.* 2002;62(4):1385-1394.
24. Pemberton LF, Rugtetti A, Taylor-Papadimitriou J, Gendler SJ. The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells. *J Biol Chem.* 1996;271(4):2332-2340.
25. Zivna M, Hulkova H, Matignon M, et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. *Am J Hum Genet.* 2009;85(2):204-213.
26. Bleyer AJ, Zivna M, Julkova H, et al. Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone. *Clin Nephrol.* 2010;74(6):411-422.
27. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. *Nat Genet.* 1997;17(4):384-385.
28. Bellanne-Chantelot C, Chauveau D, Gautier JF, et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. *Ann Intern Med.* 2004;140(7):510-517.
29. Decramer S, Parant O, Beaufile S, et al. Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperchogenic kidneys. *J Am Soc Nephrol.* 2007;18(3):923-933.
30. Verhave JC, Bech AP, Wetzels JF, Nijenhuis T. Hepatocyte nuclear factor 1beta-associated kidney disease: more than renal cysts and diabetes. *J Am Soc Nephrol.* 2016;27(2):345-353.
31. Massa F, Garbay S, Bouvier R, et al. Hepatocyte nuclear factor 1beta controls nephron tubular development. *Development.* 2013;140(4):886-896.
32. Faguer S, Chassaing N, Bandin F, et al. The HNF1B score is a simple tool to select patients for HNF1B gene analysis. *Kidney Int.* 2014;86(5):1007-1015.
33. Bolar NA, Golzio C, Zivna M, et al. Heterozygous loss-of-function SEC61A1 mutations cause autosomal-dominant tubulo-interstitial and glomerulocystic kidney disease with anemia. *Am J Hum Genet.* 2016;99(1):174-187.
34. Saleh M, Kamath BM, Chitayat D. Alagille syndrome: clinical perspectives. *Appl Clin Genet.* 2016;9:75-82.
35. Kohlhase J. Townes-brocks syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, eds. *GeneReviews*. Seattle, WA: University of Washington; 2007.
36. Upadhyay J, Steenkamp DW, Milunsky JM. The syndrome of hypoparathyroidism, deafness, and renal anomalies. *Endocr Pract.* 2013;19(6):1035-1042.
37. Belge H, Dahan K, Cambier JF, et al. Clinical and mutational spectrum of hypoparathyroidism, deafness and renal dysplasia syndrome [e-pub ahead of print]. *Nephrol Dial Transplant.* 2016.
38. Hartmannova H, Piherova L, Tauchmannova K, et al. Acadian variant of Fanconi syndrome is caused by mitochondrial respiratory chain complex I deficiency due to a non-coding mutation in complex I assembly factor NDUFAF6 [e-pub ahead of print]. *Hum Mol Genet.* 2016.